Bibliographic Details
| Title: |
Intraperitoneal Chemotherapy for Peritoneal Metastases: Technical Innovations, Preclinical and Clinical Advances and Future Perspectives. |
| Authors: |
Christou, Niki1,2,3 (AUTHOR) christou.niki19@gmail.com, Auger, Clément3 (AUTHOR) serge.battu@unilim.fr, Battu, Serge3 (AUTHOR) fabrice.lalloue@unilim.fr, Lalloué, Fabrice3 (AUTHOR) jauberte@unilim.fr, Jauberteau-Marchan, Marie-Odile3 (AUTHOR) celine.hervieu@unilim.fr, Hervieu, Céline3 (AUTHOR) mireille.verdier-sage@unilim.fr, Verdier, Mireille3 (AUTHOR), Mathonnet, Muriel1,3 (AUTHOR), Moro, Loredana (AUTHOR) |
| Source: |
Biology (2079-7737). Mar2021, Vol. 10 Issue 3, p225. 1p. |
| Subject Terms: |
*HYPERTHERMIC intraperitoneal chemotherapy, *CANCER chemotherapy, *APPENDIX (Anatomy), *METASTASIS, *RANDOMIZED controlled trials, *MOLECULAR genetics, *TREATMENT effectiveness |
| Abstract: |
Simple Summary: The aim of this review is to emphazise the evolution of intraperitoneal chemotherapy for peritoneal metastasis. Over the last past decade, both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have evolved aiming at improving global and recurrence-free survival of malignant peritoneal diseases. We are waiting now more large randomized controlled trials to demonstrate the efficacy of such treatments. (1) Background: Tumors of the peritoneal serosa are called peritoneal carcinosis. Their origin may be primary by primitive involvement of the peritoneum (peritoneal pseudomyxoma, peritoneal mesothelioma, etc.). This damage to the peritoneum can also be a consequence of the dissipation of cancers—in particular, digestive (stomach, pancreas, colorectal, appendix) and gynecological (ovaries) ones in the form of metastases. The aim of the treatment is a maximal reduction of the macroscopic disease called "cytoreduction" in combination with hyperthermic intra-abdominal chemotherapy to treat residual microscopic lesions. (2) Methods: In this narrative review, we fundamentally synthetize the evolution of this process over time and its impact on clinical applications. (3) Results: Over the last past decade, different evolutions concerning both delivery modes and conditions concerning hyperthermic intra-abdominal chemotherapy have been realized. (4) Conclusion: The final objective of these evolutions is the improvement of the global and recurrence-free survival of primary and secondary malignant peritoneal pathologies. However, more large randomized controlled trials are needed to demonstrate the efficacy of such treatments with the help of molecular biology and genetics. [ABSTRACT FROM AUTHOR] |
|
Copyright of Biology (2079-7737) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
